- Home
- TRU vs UTHR Comparison
TRU vs UTHR Comparison
Compare TRU & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- UTHR
- Stock Information
- Founded
- TRU 1968
- UTHR 1996
- Country
- TRU United States
- UTHR United States
- Employees
- TRU N/A
- UTHR N/A
- Industry
- TRU Finance: Consumer Services
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- TRU Finance
- UTHR Health Care
- Exchange
- TRU Nasdaq
- UTHR Nasdaq
- Market Cap
- TRU 17.2B
- UTHR 13.8B
- IPO Year
- TRU 2015
- UTHR 1999
- Fundamental
- Price
- TRU $91.66
- UTHR $403.68
- Analyst Decision
- TRU Buy
- UTHR Strong Buy
- Analyst Count
- TRU 12
- UTHR 15
- Target Price
- TRU $115.33
- UTHR $449.13
- AVG Volume (30 Days)
- TRU 2.3M
- UTHR 884.7K
- Earning Date
- TRU 10-22-2025
- UTHR 10-29-2025
- Dividend Yield
- TRU 0.50%
- UTHR N/A
- EPS Growth
- TRU N/A
- UTHR 17.94
- EPS
- TRU 1.99
- UTHR 25.63
- Revenue
- TRU $4,357,300,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- TRU $7.99
- UTHR $13.89
- Revenue Next Year
- TRU $8.83
- UTHR $5.68
- P/E Ratio
- TRU $45.96
- UTHR $15.74
- Revenue Growth
- TRU 9.34
- UTHR 17.62
- 52 Week Low
- TRU $66.38
- UTHR $266.98
- 52 Week High
- TRU $113.17
- UTHR $436.95
- Technical
- Relative Strength Index (RSI)
- TRU 52.96
- UTHR 68.95
- Support Level
- TRU $88.34
- UTHR $396.12
- Resistance Level
- TRU $94.27
- UTHR $407.06
- Average True Range (ATR)
- TRU 3.05
- UTHR 13.53
- MACD
- TRU 0.25
- UTHR 2.19
- Stochastic Oscillator
- TRU 65.09
- UTHR 75.31
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.